Semaglutide works by activating only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors
These compounded options have provided affordable access for millions of people but face ongoing regulatory uncertainty
Lets say a patient has tried structured dieting, increased physical activity, and maybe even metformin, but their weight hasnt budged and their blood sugar keeps rising
An important reason to treat obesity is to prevent secondary conditions like diabetes or cardiovascular disease
### AOD-9604 Mechanism of Action AOD-9604 is believed to promote **fat loss** through: - Stimulation of lipolysis in adipose tissue via beta-3 adrenergic receptor pathways - Inhibition of lipogenesis (new fat formation) - No effect on growth hormone receptors (does not promote tissue growth) - No effect on IGF-1 levels or blood glucose Importantly, AOD-9604 does **not** suppress appetite or affect food intake it is purely a lipolytic **fat loss peptide**
This prevents the breakdown of dietary fats into free fatty acids and monoglycerides that can be absorbed, leading to a reduction in caloric intake and weight loss [24]
